Our group and others have reported on the potential neuroprotective effects of maple syrup against Alzheimer’s disease (AD) and amyotrophic lateral sclerosis. Herein, we sought to further evaluate the anti-AD effects of a food-grade phenolic-enriched maple syrup extract (MSX) using biophysical, in vitro, and in vivo assays. MSX (30-500 µg/mL) inhibited acetylcholinesterase by 8.4 to 43.3% and reduced Aβ fibrillation (Thioflavin T assay) in a concentration dependent manner (18.9-63.5% reduction from 50-500 μg/mL). The anti-Aβ fibrillation effects of MSX were further supported by transmission electron microscopy, circular dichroism, dynamic light scattering, and zeta potential assays. MSX (50 and 100 μg/mL) decreased H2O2-induced nitric oxide production in murine BV-2 microglial cells by 10 and 22.1%, respectively, and reduced the media levels of inflammatory cytokinesincluding IL-6, PGE2, and TNFα by 19.9, 74.8, and 87.6%, respectively. MSX (100 μg/mL) also reduced the cytotoxicity of human SH-SY5Y neuronal cells after exposure to BV-cells conditioned media and increased the cell viability of the SH-SY5Y cells by 17.7%. MSX (100 μg/mL) protected Caenorhabditis elegans from Aβ induced neurotoxicity and paralysis and increased the lifespan of C. elegans by 10.4%. Therefore, the data accumulated from the current study supports further investigation of the anti-AD effects of MSX in rodent models.

Further investigations into the neuroprotective effects of a phenolic-enriched Maple Syrup Extract (MSX)

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.